ENDPOINTS

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint investors

Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an experimental pneumococcal vaccine in infants. The company said VAX-24 was non-inferior to Pfizer' ...

Mar 31, 2025 - 20:07
 0
Vaxcyte's Phase 2 pneumococcal vaccine data disappoint investors
Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an experimental pneumococcal vaccine in infants. The company said VAX-24 was non-inferior to Pfizer' ...
Read More

Tags:

Previous Article

FDA reschedules opioid-focused advisory meeting

Next Article

Watch SpaceX Launch Historic Fram2 Crewed Mission over Earth’s Poles Tonight

Related Posts

Belgian biotech Augustine gets $85M for neuro and cardiometabolic pills

Belgian biotech Augustine gets $85M for neuro and cardi...

Mar 24, 2025  0

Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial

Novo Nordisk’s CagriSema shows 15.7% weight loss in sec...

Mar 10, 2025  0

FDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on drug manufacturing; AbbVie’s move into the obesity market; and more

FDA and NIH nominees sail through Senate hearings; Tari...

Mar 8, 2025  0